Palisade Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Palisade Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,593	Closed	-$424K	–	542
2015 Q1	$424K	Hold	3,593	–	–	0.01%	457
2014 Q4	$427K	Sell	3,593 -253	-7%	-$28.5K	0.01%	438
2014 Q3	$432K	Sell	3,846 -170	-4%	-$16.2K	0.01%	440
2014 Q2	$380K	Sell	4,016 -751	-16%	-$52.7K	0.01%	435
2014 Q1	$337K	Sell	4,767 -3,615	-43%	-$286K	0.01%	429
2013 Q4	$623K	Sell	8,382 -4,488	-35%	-$313K	0.02%	376
2013 Q3	$976K	Sell	12,870 -2,129	-14%	-$169K	0.03%	351
2013 Q2	$1.2M	Buy	+14,999	New	+$1.1M	0.03%	352

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Palisade Capital Management's VRTX Position: Q2 2015 in Review

Palisade Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 3,593 shares — an estimated $424K sold.

Palisade Capital Management first reported a position in VRTX in Q2 2013 and held it in 8 quarters. The position peaked at $1.2M in Q2 2013. 501 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

Palisade Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Palisade Capital Management sold 3,593 Vertex Pharmaceuticals shares in Q2 2015, an estimated $424K.
Palisade Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Palisade Capital Management's Vertex Pharmaceuticals position peaked at $1.2M in Q2 2013.
501 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Palisade Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.